The Type 2 Diabetes Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Type 2 Diabetes Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

 

Unlock detailed insights into the Type 2 Diabetes Market by downloading the comprehensive report from DelveInsight @ Type 2 Diabetes Therapeutics Market

 

Key Takeaways from the Type 2 Diabetes Market Report

• The Type 2 Diabetes Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
• In September 2024:- Novo Nordisk A/S- The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
• As per the analysis, the risk of type 2 diabetes increases with age, especially after 45, because people tend to exercise less and gain weight.
• According to Diabetes UK, in 2018, 12.3 million people in the UK were at risk of developing type 2 diabetes due to their lifestyle.
• According to the American Diabetes Association (2024), in adults with type 2 diabetes who have not achieved their individualized weight goals, additional weight management interventions (e.g., intensification of lifestyle modifications, structured weight management programs, pharmacologic agents, or metabolic surgery, as appropriate) are recommended.
• According to the CDC, 4.6 to 9.2 percent of pregnancies may be affected by gestational diabetes. In up to 10 percent of them, the mother is diagnosed with type 2 diabetes just after the pregnancy. The rest of these women have a 35 to 60 percent chance of developing type 2 diabetes within 10 to 20 years.
• The leading Type 2 Diabetes Companies such as Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others 
• Promising Type-2 Diabetes Therapies such as NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.

 

Gain a competitive edge in the Type 2 Diabetes Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Type 2 Diabetes Treatment Drugs

 

Type 2 Diabetes Prevalence

• Total Type 2 Diabetes Prevalent Cases
• Total Type 2 Diabetes Diagnosed Prevalent Cases
• Total Type 2 Diabetes Gender-specific Cases
• Total Type 2 Diabetes Age-specific Cases
• Type 2 Diabetes Treated Cases

 

Type 2 Diabetes Treatment Market

The primary treatment for type 2 diabetes includes lifestyle changes, such as diet and exercise, alongside approved therapies like metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Recent advancements include the approval of BRENZAVVY by TheracosBio in 2023 and TWYMEEG by Sumitomo Pharma/Poxel in 2021, which enhance treatment options and glucose management.Focusing on the chronic and severe nature of TD1 and TD2, the treatment approach for them is quite comprehensive; regularization of glucose metabolism and control of risk factors (e.g., arterial hypertension) is the key treatment target for type 2 diabetes. Metformin, which is the most commonly prescribed initial treatment for the condition, lowers blood sugar levels for patients by improving how their body handles insulin. Many other therapies including Alpha-glucosidase inhibitors, Amylin analogs, or agonists and sodium-glucose cotransporter-2 inhibitors, etc. are prescribed to treat type 2 diabetes.

 

Type 2 Diabetes Market Insights

Type 2 diabetes is a serious, life-threatening condition with no cure, serving as a risk factor for numerous other disorders. While there is no established cure, devices are available to monitor glucose levels, and treatment involves both oral and injectable medications, alongside lifestyle changes like a healthy diet and regular exercise. Metformin, the most commonly prescribed initial treatment, improves insulin sensitivity to lower blood sugar. Alpha-glucosidase inhibitors (AGIs), such as Glucobay (acarbose) and Glyset (miglitol), delay carbohydrate absorption, reducing post-meal glucose spikes and HbA1c levels. Amylin analogs, like Symlin, are injectable drugs that promote weight loss and help control glucose but require careful monitoring to prevent hypoglycemia. Novo Nordisk’s SAXENDA (liraglutide) helps manage T2D by improving glycemic control, promoting weight loss, enhancing β-cell function, and reducing HbA1c levels.

 

Discover key developments and opportunities in the Type 2 Diabetes Market. Click here to learn more from DelveInsight’s latest report @ Type 2 Diabetes Market Size

 

Type 2 Diabetes Marketed Drugs

• Rybelsus: Novo Nordisk

In September 2019, the US Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve the control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.

• Trijardy XR: Eli Lilly and Boehringer Ingelheim

In January 2020, the US FDA approved Trijardy XR to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy XR provides three type 2 diabetes medicines in one pill, including Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release. In the US, both Jardiance and Tradjenta are once-daily tablets used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug is being marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company

 

Type 2 Diabetes Emerging Drugs

• Danuglipron (PF-06882961) – Pfizer

Danuglipron (PF-06882961), an oral small-molecule, GLP-1R agonist being developed by Pfizer. The drug is currently in Phase II of development. In Phase I, danuglipron demonstrated robust reductions in fasting plasma glucose of -66.6, -80.6, and -89.7 mg/dL at doses of 15, 70, and 120 mg respectively, compared to a -24.8 mg/dL reduction for placebo. Danuglipron also reduced HbA1c by -0.9, -1.2, and -1.2% at doses of 15, 70 and 120 mg respectively, compared to a -0.4% reduction for placebo-treated subjects. The results with the highest dose tested in a phase 2 trial show promising HbA1c lowering and weight loss.

• ORMD-0801- Oramed

Oramed’s oral insulin ORMD-0801 is a Phase III drug has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. The drug is being evaluated in two Phase III trials ORA-D-013-1 and ORA-D-013-2 with the company anticipating the approval in 2024. Other Noverl emerging drugs in teh Type-2 Diabetes treatment market in teh different clinical trials phases include – Research programme: type 2 diabetes mellitus therapeutics: Abarceo Pharma, NRDN-101: Neurodon, ECC5004: Eccogene, KN056: Suzhou Alphamab Co., Ltd., XW014: Sciwind Biosciences, RGT001-075: Regor Pharmaceuticals, HR17031: Jiangsu Hengrui Medicine Co, CPL207280: Celon Pharma, THDB0206: Tonghua Dongbao Pharmaceutical, LY-3209590: Eli Lilly and Company, Insulin icodec: Novo Nordisk, and others.

 

Type 2 Diabetes Market Outlook

The Type 2 diabetes Market is a crowded and competitive landscape with multiple, generic, and biosimilar drugs entering the market. The diabetes drugs market is moderately fragmented, with few significant and generic players. The market competitors are launching not only novel pharmaceuticals and therapies but also equipment and tools that can be used in the treatment and diagnosis of type 2 diabetes. The expansion of the healthcare sector and favorable government regulations are fueling the growth of the type 2 diabetes market.

 

Download DelveInsight’s Type 2 Diabetes Market report today and stay ahead in this rapidly evolving field. @ Type 2 Diabetes Clinical Trials

 

Scope of the Type 2 Diabetes Market Report

• Coverage- 7MM
• Type 2 Diabetes Companies- Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., and others.
• Type 2 Diabetes Therapies- NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.
• Type 2 Diabetes Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Type 2 Diabetes Unmet Needs, KOL’s views, Analyst’s views, Type 2 Diabetes Market Access and Reimbursement

 

Download the report to understand which factors are driving Type 2 Diabetes Market Trends @ Type 2 Diabetes Market Trends

 

Table of Content

1. Report Introduction

2. Executive Summary of Type 2 Diabetes

3. SWOT Analysis of Type 2 Diabetes

4. Type 2 Diabetes: Patient Share (%) Overview at a Glance

5. Type 2 Diabetes: Market Overview (%) at a Glance

6. Disease Background and Overview

7. Type 2 Diabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Type 2 Diabetes

9. Current Type 2 Diabetes Treatment and Medical Practices

10. Type 2 Diabetes Patient Journey

11. Type 2 Diabetes Unmet Needs

12. Key Endpoint of Clinical Trials

13. Type 2 Diabetes Marketed Products

14. Emerging Type 2 Diabetes Therapies

15. Conjoint Analysis of Type 2 Diabetes Therapies

16. Type 2 Diabetes: Market Size of 7MM

17. Country-Wise Market Analysis (2020–2034)

18. Market Access and Reimbursement of Drug induced dyskinesia

19. Type 2 Diabetes Market drivers

20. Type 2 Diabetes Market barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/